載入...
Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg(®)) in children with relapsed/refractory myeloid leukemia
BACKGROUND: Gemtuzumab ozogamicin (GO) is a cytotoxic anti-CD33 monoclonal antibody that has given promising preliminary results in adult myeloid CD33+ AML. We conducted a retrospective multicenter study of 12 children treated with GO on a compassionate basis (median age 5.5 y). Three patients (2 MD...
Na minha lista:
Main Authors: | , , , , , , , |
---|---|
格式: | Artigo |
語言: | Inglês |
出版: |
BioMed Central
2006
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1523361/ https://ncbi.nlm.nih.gov/pubmed/16805911 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-6-172 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|